What's Going On With Neutrogena Maker Kenvue Stock On Thursday?
Kenvue Inc. (NYSE:KVUE) shares are down during Thursday’s premarket session, with no news. Over the last six months, the company’s stock has fallen by around 15%.
In January, the company said it is moving forward with its acquisition process by Kimberly-Clark Corporation (NYSE:KMB).
Kenvue and Kimberly-Clark shareholders overwhelmingly approved the proposals necessary for Kimberly-Clark to complete its acquisition of Kenvue, with approximately 99% of shares voted in favor at Kenvue’s Special Meeting. The transaction is expected to close in the second half of 2026, pending regulatory approvals.
The approval marks a significant milestone in creating a global health and wellness leader, with Kenvue’s CEO, Kirk Perry, expressing confidence in the growth opportunities ahead for the combined company.
This merger aims to enhance innovation and expand access to their trusted brands, which include well-known names like Tylenol and Listerine.
In November 2025, a Texas judge declined to halt an upcoming shareholder payout by Texas Attorney General Ken Paxton to restrict Kenvue’s handling and marketing of Tylenol amid ongoing litigation over the product’s safety for pregnant women.
The ruling allows Kenvue to proceed with its planned dividend while the broader dispute continues.
Technical Analysis
Kenvue stock is currently trading 4.6% above its 20-day simple moving average (SMA) and 10.7% above its 100-day SMA, demonstrating some short-term strength. However, shares have decreased by 11.55% over the past 12 months and are positioned closer to their 52-week lows than highs.
The RSI is at 73.07, indicating that the stock is in overbought territory, which could suggest a potential pullback. Meanwhile, the MACD is above its signal line, indicating bullish momentum.
The combination of overbought RSI and bullish MACD suggests mixed momentum, indicating that while the stock has been strong, it may be due for a correction.
- Key Resistance: $19.00
- Key Support: $16.50
Earnings & Analyst Outlook
Kenvue is set to report earnings on Feb. 17, 2026.
- EPS Estimate: 22 cents (Down from 26 cents YoY)
- Revenue Estimate: $3.70 billion (Up from $3.66 billion YoY)
- Valuation: P/E of 24.7x (Indicates fair valuation)
Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $20.18. Recent analyst moves include:
- Jefferies: Downgraded to Hold (Lowers Target to $18.00) (Jan. 30)
- Barclays: Equal-Weight (Raises Target to $18.00) (Nov. 10, 2025)
- Canaccord Genuity: Downgraded to Hold (Lowers Target to $15.00) (Oct. 29, 2025)
Benzinga Edge Rankings
Benzinga Edge scorecard for Kenvue
- Value: Weak (Score: 30.35) — Trading at a steep premium relative to peers.
- Momentum: Weak (Score: 14.44) — Stock is underperforming the broader market.
The Verdict: Kenvue’s Benzinga Edge signal reveals a challenging landscape as both Value and Momentum scores indicate weakness. Investors should remain cautious as the stock navigates through company-specific challenges while preparing for upcoming earnings.
KVUE Price Action: Kenvue shares were down 0.32% at $18.48 during premarket trading on Thursday, according to Benzinga Pro data.
Piotr Swat via Shutterstock